Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02225119 · ClinicalTrials.gov registry record

The Focal Electro-Oculogram in Macular Disease

A clinical trial of Age-related Macular Degeneration and Macular Degeneration, sponsored by National Eye Institute (NEI).

Completed
Registry status
39
Enrollment target
1
Study location

NCT02225119: Completed study of Age-related Macular Degeneration and Macular Degeneration, sponsored by National Eye Institute (NEI).

NCT02225119 is a study of Age-related Macular Degeneration and Macular Degeneration that has completed, run by National Eye Institute (NEI). The registered enrollment target is 39 participants, below the 1,507-participant average among 74 other Age-related Macular Degeneration trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02225119, a study of Age-related Macular Degeneration and Macular Degeneration, has completed, sponsored by National Eye Institute (NEI).

COMPLETED
Registry status
39 participants
Enrollment target
1
Study location

Study Summary

Background: \- Maculopathies are eye conditions that affect the center of the retina. Retina health depends on the retinal pigment epithelium (RPE), a layer behind the retina. A new test may measure the health of the central retina and RPE. Objective: \- To use the focal electro-oculogram (EOG) test to understand how the central retina and RPE are affected in maculopathies. Eligibility: * People at least 10 years old with a maculopathy. * Healthy volunteers with visual acuity of 20/20 or better in at least one eye. Design: * Participants will be screened with medical and eye history and an eye exam. Pictures will be taken of the eyes. * Their eyes may be dilated. * They may have a field test. They will look into a lens and press a button when they see a light. First, they may sit in the dark for 40 minutes. * Participants will have 1-7 visits over 18 months. * Their vision will be tested and eye pressure measured. * Their pupils will be dilated with eye drops and researchers may take pictures of the retina and the inside of the eye, and measure the thickness of the retina. * Participants will have an electro-oculogram. They will look at a 2 LED lights and follow them back and forth for 10 seconds once per minute. Participants will be in darkness for 15 minutes and in light for 20 minutes. One skin electrode will be placed on the nose and one next to the eye. * Participants with maculopathy will also have: * Field test. * Electroretinogram. Participants will get numbing eye drops and special contact lenses. A small metal electrode will be taped to the forehead. Participants will watch flashing lights and try not to blink. First, they may sit in the dark for 40 minutes.

Primary Outcome

to develop a method for recording the focal EOG in response to a central light stimulus

Study Locations (1)

Maryland

  • National Institutes of Health Clinical Center - Bethesda

Trial Details

FieldValue
Enrollment Target 39 participants
Start Date 2015-02-06
Est. Completion 2020-02-28
National Eye Institute (NEI)

221 total trials

What the finished NCT02225119 record still lists

NCT02225119 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 39 participants, a relatively small participant target, below the 1,507-participant average among 74 other Age-related Macular Degeneration trials with a reported enrollment target (97% lower).

The record links to 2 conditions, with Age-related Macular Degeneration appearing as the primary indexed condition, and to 0 interventions.

NCT02225119 reports a single indexed study location in Maryland.

Frequently Asked Questions

What is clinical trial NCT02225119 about?

NCT02225119 is a clinical study titled "The Focal Electro-Oculogram in Macular Disease". Background: \- Maculopathies are eye conditions that affect the center of the retina. Retina health depends on the retinal pigment epithelium (RPE), a layer behind the retina. A new test may measure the health of the central retina and RPE. Objective: \- To use the focal electro-oculogram (EOG) t...

What is the current status of trial NCT02225119?

This trial is currently completed. The enrollment target is 39 participants. The study started on 2015-02-06. Estimated completion is 2020-02-28.

What conditions does trial NCT02225119 study?

This clinical trial studies the following conditions: Age-related Macular Degeneration, Macular Degeneration.

Who is sponsoring clinical trial NCT02225119?

This trial is sponsored by National Eye Institute (NEI), which has 221 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02225119 being conducted?

This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Age-related Macular Degeneration

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT02225119's enrollment target sits among peer trials

39 55th of 74 higher than 20 of 74 other Age-related Macular Degeneration trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Age-related Macular Degeneration trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03465592 · 39 participants · Phase 1

    Trial of Nivolumab Following Partially Human Leukocyte Antigen (HLA) Mismatched BMT in Children & Adults With Sarcoma

  • NCT03961776 · 39 participants

    Monitoring Treatment Response With On-board DWI During Neo-adjuvant Chemo-radiation for Rectal Cancer Using Magnetic Resonance-guided-radiotherapy Systems

  • NCT04050280 · 39 participants · Phase 2

    CLAG-GO for Patients With Persistent, Relapsed or Refractory AML

  • NCT04190862 · 39 participants · Phase 1

    E-CEL UVEC as an Adjunct Cell Therapy for Treatment of Anal Fistulas

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT02225119, the US trial registry maintained by the National Library of Medicine. NCT02225119 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.